Sheet 1 of 3

APPLICATION NO. PTO-1449 REPRODUCED ATTORNEY DOCKET NO. 1290.1019-013 Divisional of 09/249,011 filed INFORMATION DISCLOSURE CITATION February 12, 1999 IN AN APPLICATION July 27, 2000 APPLICANT 09/626731 Man Sung Co, et al. (Use several sheets if necessary) GROUP FILING DATE July 27, 2000 1644 U.S. PATENT DOCUMENTS FILING DATE SUB-EXAM'-CLASS CLASS DATE NAME DOCUMENT NUMBER INER APPROPRIATE INI-TIAL 10/08/96 Co et al. 424 133.1 5,562,903 AB 5,585,089 12/17/96 Queen et al. 424 133.1 AC 5,622,701 04/22/97 424 153.1 Berg 69.6 435 AD 04/29/97 Winter et al. 5,624,821 ΑE 07/15/97 Winter et al. 435 252.3 5,648,260 AF 12/02/97 Queen et al. 530 387.3 5,693,762 5,869,050 02/09/99 de Boer et al. 424 156.1 172.2 03/14/95 de Boer et al. 435 AΗ 5,397,703 137.1 5,747,034 05/05/98 de Boer et al. 424 ΑJ FOREIGN PATENT DOCUMENTS SUB-TRANSLATION COUNTRY CLASS CLASS YES DOCUMENT NUMBER DATE AL 94/01547 20-JAN-94 WO 95/03408 WO 02-FEB-95 AN 98/19706 14-MAY-98 WO AΡ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Azuma, M. et al., "B70 antigen is a second ligand for CTLA-2 and CD28," Nature 366:76-79 (1993). Berzofsky, J.A. and Berkower, I.J., "Antigen-Antibody Interaction," In AS Fundamental Immunology, W.E. Paul eds. (NY: Raven Press), pp. 595-644 (1984).Chen, L. et al., "Costimulation of Antitumor Immunity by the B7 Counter receptor for the T Lymphocyte Molecules CD28 and CTLA-4, " Cell 71:1093-1102 (1992). DATE CONSIDERED EXAMINER GAMBEL 3/240L

DTO 1440 DEED	PODLICED	ATTORNEY DOCKET NO.	APPLICATION NO.			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 27, 2000		1290.1019-013	Divisional of 09/249,011 filed February 12, 1999			
		APPLICANT Man Sung Co, et al.	04/626731			
	(Use several sheets if necessary)	FILING DATE July 27, 2000	group 1644			
	OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent	: Pages, Etc.)			
PG AU	Co, M.S. et al., "Chimeric for the CD33 Antigen," The	and Humanized Antibodi J. of Immunology 148(4	es with Specificity):1149-1154 (1992).			
AV	Cole, M.S. et al., "Human I Nonmitogenic to T cells,"					
WA	Daikh, D. et al., "The CD28 autoimmune disease," J. of	3-B7 costimulatory path Leukocyte Biol. 62:156	way and its role in 5-162 (1997).			
AX	immunoglobulin in γ heavy o	Ellison, J. and Hood, J., "Linkage and sequence homology of two human immunoglobulin in γ heavy chain constant region genes," <i>Proc. Natl. Acad. Sci. USA</i> 79:1984-1988 (1982).				
AY	Monocytes and Activated B I	Engel, P. et al., "The B7-2 (B70) Costimulatory Molecule Expressed by Monocytes and Activated B Lymphocytes Is the CD86 Differentiation antigen," Blood 84(5):1402-1407 (1994).				
AZ	Fleischer, J. et al., "Diff (B7-1) and CD86 (B7-2) on h 89:592-598 (1996).	ferential expression and numan peripheral blood	nd function of CD80 monocytes," Immunology			
AR	² in Human Monocytes After U.	Fujihara, M. et al., "Decreased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B Irradiation: Its Involvement in Inactivation of Allogenecity," Blood 87(6):2386-2393 (1996).				
AS	Glaser, S.M. et al., "Disse Anti-Tac Antibody," The J.	ection of the Combining of Immunology 149(8):	Site in a Humanized 2607-2614 (1992).			
AT	Antibody with Specificity for Both E- and P-Selectin, " The J. of Immunology 160:1029-1035 (1998).					
AU						
AV	Jefferis, R. and Lund, J., effector sites, Department Birmingham, pp.115-126.					
AW	Levitt, M. "Molecular Dynar 168:595-620 (1983).	mics of Native Protein,	" J. Mol. Biol.			
AX	by IgG," In Protein Engineer and Therapeutic Application	Morrisons, S.L. et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993).				
N AY	Ohki, O. et al., "Functional on Langerhans cells in atom 136:838-845 (1997).	al CD86 (B7-2/B70) is poic dermatitis," <i>Britis</i>	oredominantly expressed sh J. of Dermatology			
EXAMINER	Gambe 3/29/01	DATE CONSIDERED				
		<u></u>				

PTO-144	O DEDDO	ADIVOTA	ATTORNEY DOCKET NO.	APPLICATION NO.		
P10-144	9 REPRO	buceb	1290.1019-013	Divisional of		
	INFORMATION DISCLOSURE CITATION IN AN APPLICATION			09/249,011 filed		
		IN AN APPLICATION		February 12, 1999		
July 27, 2000			APPLICANT Man Sung Co, et al.	09/626731		
(Use	e sev	reral sheets if necessary)	FILING DATE July 27, 2000	GROUP 1644		
		OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent	Pages, Etc.)		
M	AZ2	Queen, C. et al., "A human: receptor," Proc. Natl. Acad				
	AR3	Reiser, H. and Schneeberger B7-2 in hapten-induced con- 885 (1996).	neeberger, E.E, "Expression and function of B7-1 and aced contact sensitivity," Eur. J. Immunol. 26:880-			
	AS3	Reiser, H. and Stadecker, M.J., "Costimulatory B7 Molecules in the Pathogenesis of Infection and Autoimmune Diseases," <i>Mechanisms of Disease</i> 335(18):1369-1377 (1996).				
	AT3	Rugtveit, J. et al., "Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD), " Clin. Exp. Immunol. 110:104-113 (1997).				
	AU3	Shalaby, M.R. et al., "Deve Reactive with Cytotoxic Lyn HER2 Protooncogene," J. Exp	mphocytes and Tumor Cel	ls Overexpressing the		
	AV3	Tempest, P.R. et al., "Reshaping A Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection In Vivo," <i>Bio/Technology</i> 9:266-271 (1991).				
	AW3	Townsend, S.E. and Allison, J.P., "Tumor Rejection After Direct Costimulation of CD8+ T Cells by B7-Transfected Melanoma Cells," Science 259:368-369 (1993).				
	Yokozeki, H. et al., "Functional CD86 (B7-B70) on Cultured Human Langerhans Cells," The Society for Investigative Dermatology, Inc. 106:147-153 (1996).					
	AY3	Liu, Z-X., et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients With Crohn's Disease," Scand J. Gastroenterol, 32(12):1241-6 (1997).				
	A23	Lisa A. Damico, et al., "Pharmacokinetics of IV Administered Murine Anti-Human B7.1 and Murine Anti-Human B7.2 in Cynomoglus Monkeys" Abstract, 17th Annual Scientific Meeting, January 9, 1998.				
	AR4	Cromwell, M.A. and Goldman Reconstituted Nod-Scid Mouse Cell Activation, Experime	se as model of Superar	ntigen-Induced Human T		
4	AS4	Bluestone, J.A., "Costimula Clinical Transplantation 1		organ transplantation,"		
EXAMI	NER /	Smar 3/26/02	DATE CONSIDERED			
	G	1211112E 3100100				

Sheet 1-61

			Shee	
APPLICANT FACSIMILE OF FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.	
O P E S	PATENT AND TRADEMARK OFFICE	GNN-5315DV2	09/626,731	
/ LIST OF PUBLICATIONS	CITED BY APPLICANT	APPLICANT		
್ತ್ರಿಯಿಗೆ ಪ್ರ (Use several she	ets if necessary)	Man Sung Co et al.		
, MAY E	, ,	FILING DATE	GROUP	
Se se		July 27, 2000	1644	
TRADENT	U.S. PATENT DO	CUMENTS		

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
MU	B1	6,084,067	07/00	Freeman et al.	530	350	
1			FORE	EIGN PATENT DOCUMENTS			•
		DOCUMENT NUMBÉR	DATE	Country	CLASS	SUBCLASS	TRANSLATION YES N
	B2	WO 95/34320	12/95	PCT			
	ВЗ	WO 96/14865	05/96	PCT			
	B4			g Author, Title, Date, Pertinent Pa	 	onoclonal	antibodies
				Digestive Diseases and Science			
	B5	induction of	Bree, A.G. et al., "Humanized anti-B7-1 and anti-B7-2 antibodies prevent antigen specific induction of immunity in nonhuman primates immunized with tetanus toxoid and mumps virus vaccine," Blood, 94(10) Suppl. 1 part 1, p. 439a (1999) Hathcock, K.S. et al., "Role of the CD28-B7 costimulatory pathways in T cell-dependent cell responses," Advances in Immunology, 62:131-166 (1996)				
	B6	cell respons					
	B7	treatment or	Lenschow, D.J. et al., "Differential effects of anti-B7-1 and anti-B7-2 monoclonal anti-treatment on the development of diabetes in the nonobese diabetic mouse," <i>J. Exp.</i> 181:1145-1155 (1995)				
	В8	and anti-B7-	1 antibodie	Inhibition of transplant rejection f s," <i>Transplantation</i> , 60:1171-117	8 (1995)		
m	B9	with potentia	I use in the	Generation of humanized Fab fra prevention of graft rejection and andbouwkundige en toegepaste b	development	of graft-v	ersus-host

Examiner

3/29/02 GAMBEL

Date Considered

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.